Article Details

After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B

Retrieved on: 2021-03-30 12:00:00

Tags for this article:

Click the tags to see associated articles and topics

After Pfizer cancer deal, Pyxis Oncology nabs a hefty $152M series B. View article details on HISWAI: https://www.fiercebiotech.com/biotech/after-pfizer-cancer-deal-pyxis-oncology-nabs-a-hefty-152m-series-b

Excerpt

A few weeks back, Pfizer out-licensed two of its antibody-drug conjugate (ADC) candidates, to be known as PYX-201 and PYX-203, to the biotech, while ...

Article found on: www.fiercebiotech.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up